论文部分内容阅读
NanoBio Corporation在2008-02-01召开的美国皮肤病学会2008年会上发表了其治疗唇疱疹新药(NB-001)和治疗甲癣新药(NB-002)的安全性和有效性数据。NanoBio所提供的数据表明,该公司研发的这2种局部用药各自的抗病毒和抗真菌作用强,无需担心其使用安全性和组织吸收。临床试验的中期数据显示,NB-001在治疗唇疱疹时表现出治愈速度快、
NanoBio Corporation published data on the safety and efficacy of the new drug for the treatment of cold sores (NB-001) and the treatment of new oncospores (NB-002) at the 2008 American Academy of Dermatology 2008 conference. The data provided by NanoBio show that the two topicals developed by the company each have strong antiviral and antifungal effects without concern for their safety of use and tissue absorption. Interim data from clinical trials show that NB-001 shows a rapid cure in the treatment of cold sores,